Credit Trends: U.S. Composite Credit Spreads Daily (Feb. 13, 2012) Feb 12

  • ID: 2059759
  • February 2012
  • Region: United States
  • Standard & Poors
1 of 2

Standard & Poor's investment-grade composite remained unchanged at 207 basis points (bps) Friday, and the speculative-grade composite spread widened by 8 bps to 655 bps. By rating, the 'AA' and 'A' spreads expanded by 1 bp each to 136 bps and 181 bps, respectively, and 'BBB' remained unchanged at 259 bps. The 'BB' spread widened by 6 bps to 464 bps, 'B' widened by 8 bps to 704 bps, and 'CCC' expanded by 13 bps to 1,074 bps. By industry, financial institutions, industrials, and telecommunications widened by 1 bp each to 321 bps, 306 bps, and 330 bps, respectively. Banks expanded by 3 bps to 342 bps, and utilities narrowed by 1 bp to 211 bps. The investment-grade and speculative-grade...

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.